Today's Top Gainer
Note:Top Gainer - Nifty 50 More
Your Directors have pleasure in presenting the Twenty-Seventh Annual Report together with the Audited Financial Statements for the financial year ended March 31, 2018.
We are also delighted to introduce a new name to the relationship you have cherished with us for long. Strides Shasun Limited is now renamed as Strides Pharma Science Limited effective July 18, 2018.
1. Financial Summary (Consolidated & Standalone)
|Particulars||Consolidated Basis||Standalone Basis|
|1.1 Financial Results|
|Operating Profit (EBIDTA)||4,906.02||75.29||6,884.33||106.14||3,532.89||54.22||3,397.75||52.39|
|Net Profit (PAT)||702.14||10.78||2,797.10||43.13||1,564.48||24.01||1,519.36||23.43|
|Reserve & Surplus||23,650.61||362.96||26,594.00||410.02||30,725.16||471.53||31,431.04||484.60|
|Operating Profit (EBIDTA)||4,906.02||75.29||6,884.33||106.14||3,532.89||54.22||3,397.75||52.39|
|Depreciation & Amortisation||1,540.35||23.64||1,261.51||19.45||778.05||11.94||700.06||10.79|
|Profit Before Tax||967.46||14.85||3,427.51||52.84||1,641.33||25.19||1,826.46||28.16|
|Share of profit / (loss) of joint ventures and associates||(167.99)||(2.58)||3.64||0.06|
|Profit Before Tax||799.47||12.27||3,431.15||52.90||1,641.33||25.19||1,826.46||28.16|
|Less: Tax Expenses|
|Current tax expenses||485.12||7.45||484.74||7.47||373.22||5.73||124.97||1.93|
|Current tax expenses relating to prior years||-||-||(6.61)||(0.10)||-||-||(6.61)||(0.10)|
|Deferred tax expenses||(107.03)||(1.64)||(3.86)||(0.06)||(15.61)||(0.24)||28.96||0.45|
|MAT Credit entitlement||(280.76)||(4.31)||159.78||2.46||(280.76)||(4.31)||159.78||2.46|
|Profit After Tax||702.14||10.78||2,797.10||43.13||1,564.48||24.01||1,519.36||23.43|
|Profit/ (Loss) from Discontinued operations||6,101.23||93.63||1,662.37||25.63||7,351.43||112.82||(433.99)||(6.69)|
|Other Comprehensive Income|
|Items that will not be reclassified to profit/ (loss)||(202.39)||(3.11)||(209.46)||(3.23)||(0.87)||(0.01)||(94.13)||(1.45)|
|Items that may be reclassified to profit/ (loss)||42.12||0.65||(233.36)||(3.60)||(196.60)||(3.02)||130.75||2.02|
|Total Other Comprehensive Income (Net of Tax)||(160.27)||(2.46)||(442.82)||(6.83)||(197.47)||(3.03)||36.62||0.56|
|Total Comprehensive income||6,643.10||101.95||4,016.65||61.93||8,718.44||133.80||1,121.99||17.30|
|Opening balance of Profit and Loss||2,184.74||33.53||(1,362.00)||(21.00)||3,930.01||60.31||3,276.90||50.52|
|Pursuant to Scheme of Amalgamation||(7,038.43)||(108.02)||-||-||(7,038.43)||(108.02)||-||-|
|Available for appropriation||1,751.00||26.87||2,635.49||40.63||5,807.49||89.13||4,362.27||67.26|
|Dividend on Equity Shares|
|Final Dividend||(402.72)||(6.18)||(357.46)||(5.49)||(402.72)||_ 6.18)||(357.46)||(5.51)|
|Tax on Final Dividend||(40.50)||(0.62)||(74.80)||(1.15)||(75.48)||(1.16)||(74.80)||(1.15)|
|Dividend to non-controlling interest shareholders||(9.78)||(0.15)||(18.49)||(0.28)|
|Tax on dividend from foreign subsidiaries (to the extent adjusted against final dividend)||(34.98)||(0.54)||-||-|
|Balance carried to Balance Sheet||1,263.02||19.38||2,184.74||33.72||5,329.29||81.79||3,930.01||60.59|
* 1 USD = INR 65.16 (Exchange Rate as on March 31, 2018)
** 1 USD = INR 64.86 (Exchange Rate as on March 31, 2017)
Previous year figures have been regrouped/ restated wherever necessary to make them comparable with those of the current year
2. Companys performance
During the reporting period, your Company recorded an overall subdued performance. While our strategy continues to build momentum, our execution did not match expectation, especially in the second half of FY 2017-18. We faced significant number of challenges primarily in our US partnered venture and the institutional business. During the year under review, we also launched our consumer health division in a difficult market environment. In hindsight, we believe we could have strategised better for improved outcomes. Additionally, we continue to struggle with the gap between our secondary and primary sales in Africa.
Despite several headwinds, our Australia operations reported a successful year. A non-US non-Australia regulated market was a win considering the significant growth that we have achieved, albeit on a low base. We also exited the India brands business that allowed us to pay significant debt and completed several corporate actions on schedule in line with our articulated strategy.
During FY 2017-18, your Company undertook several measures to develop itself as a diversified business-to-customer (B2C) player.
The US continues to be our largest market, but ~65% of our US business is currently partnered. At present, we are working very hard to reduce our dependency on our partners. We recalibrated our strategy for the US market and in FY 2018-19, we will be working towards building the frontend business ourselves. We are also pleased to report that over 50% of the revenues that were partnered have since been brought back to our own fold in terms of value. The US business still continues to be an exciting and profitable venture for a new player like us with our own frontend.
In Australia, our strategy is to bolster our leadership position. During the reporting period, our margins increased owing to operating leverage. We have also announced a transaction involving Apotex recently. We believe that our focus on markets outside the US and Australia have led to early success with some traction visible.
We have been fairly successful with our operations in the UK, parts of Europe and now South Africa. Our IP portfolio in Australia is very valuable but fungible across all other markets. Therefore, we are very focussed on leveraging it across Canada, Europe, the UK and South Africa with minimal regulatory costs. This will allow us to maximise our business in the segment and we are confident that in the next 2 to 3 years, it would emerge as a significant part of our revenue mix.
Our Africa business is shaping very well based on our robust secondary sales and we are tracking ~3x industry growth, which is great in the markets where IMS data is available. Besides, our Africa venture continues to have suboptimal base, offering us the headroom to grow; going forward, we will focus in this space.
Our institutional business had its toughest year due to compressed opportunity in malaria treatment and the margins remained almost negligible vis--vis previous years. The long-term contracts for our ARV business su_ered significantly due to increase in prices of APIs. However, the increased pricing of APIs is now a very common trend and we expect to recover soon in this segment. We have been very frugal in how we are approaching this business and it still forms a very important part of our under-recovery strategy for manufacturing operations.
During the reporting period, our R&D operations remained effective as we filed 12 ANDAs against a target of 15-20 new product ANDA filings per year. Besides, we filed 5 additional ANDAs in April and May 2018. Our focus remains unwavering in receiving the approvals in 10 months and for that we intend to take a month or two extra to ensure our filing qualities are superior.
We received fairly quick approvals for 14 new products during FY 2017-18 and three additional approvals in April and May 2018. We also secured approval for Ibuprofen Softgel capsule, which is an extremely important product, during this phase.
Going forward, we will stay focussed on building our fortunes in the US market with constant emphasise on niche products or products on which we have complete control. Furthermore, we are confident that our high compliance status across our manufacturing plants will play a key role in this endeavour.
We have completely rewired your Company with Strides 2.0 that ensures a sharpened focus on productivity and outcomes. We are confident of our course correction strategies and expect all our businesses to bounce back in the next three to four quarters.
A detailed analysis of each of the business verticals of the Company is provided in the Management Discussion and Analysis Report.
3. Corporate Updates
During the year, the Company completed several corporate actions including exiting non-core operations and markets to sharpen its focus on the B2C business and achieve leaner operations.
Corporate Actions undertaken during the year are provided herein below.
Acquisitions & JVs
1) Amneal Pharmaceuticals, Australia
Arrow Pharmaceuticals, a step-down subsidiary of the Company in Australia, acquired 100% stake in Amneal Pharmaceuticals, Australia. Amneal is engaged in the business of selling generic pharmaceutical products in Australia.
The acquisition has enabled improve Arrows generics market share thereby expanding its first-line pharmacies to 1200+ stores and provided significant synergy opportunities with 100+ molecules being common with Arrow Portfolio.
The transaction achieved closure in September 2017.
2) Controlling stake in Trinity Pharma, South Africa
Strides Pharma Asia, the Companys wholly owned subsidiary in Singapore, acquired controlling stake in Trinity Pharma ("Trinity"), a company incorporated in South Africa.
Trinity is engaged in the business of supply and distribution of generic pharmaceutical products to pharmaceutical retailers and providing services relating to regulatory and registration of products.
The transaction enabled Strides to establish a presence in the high entry market of South Africa where product dossier approval takes more than 5 years; enabling access to pipeline of more than 110 product dossiers and facilitating ARV launch in private non-tender market in South Africa.
The transaction achieved closure in January 2018.
3) JV between Amneal Pharmaceuticals and Douglas Pharmaceuticals, Australia
Amneal Pharmaceuticals, Australia, a step-down subsidiary of the Company, entered into a Joint Venture arrangement with Douglas Pharmaceuticals Australia Pty Limited, Australia.
Amneal holds approx. 50% stake in the JV Company viz., MyPak Solutions Australia Pty Ltd, Australia (formerly, MyPak Solutions Pty Ltd).
MyPak Solutions is expected to become the leading Dose Administration Aid (DAA) company in the Australian pharmaceutical and aged care industries. DAAs have been designed to assist consumers in the community to better manage their medicines and improve medication compliance.
MyPak will provide the Australian market with an end-to-end industry leading DAA solution and will enable the Company to provide the customers with a complete solution in the DAA market in Australia.
4) India Brand Business
As part of the Companys portfolio re-prioritisation, the Company exited from the India Brand Business. India Brand Business comprising of a portfolio of 130+ brands in the domains of Neurology, Psychiatry, Nutraceuticals, Gastro etc., along with the employees forming part of the said business was sold to Eris Lifesciences Limited, India ("Eris") for a consideration of Rs.410 Crore.
As part of the transaction, the Company also divested its stake in Strides Healthcare Private Limited, a subsidiary company which was catering to the Brands Business to Eris for a consideration of Rs.90 Crore.
The Company retains global rights for the divested portfolio, which have significant sales in Africa and will continue to grow the Companys emerging market business.
The transaction achieved closure in December 2017.
5) Demerger of the Commodity Active Pharmaceutical Ingredients (API) Business
During the year under review, through a composite Scheme of Arrangement between the Company, SeQuent Scientific Limited ("SeQuent") and Solara Active Pharma Sciences Limited ("Solara") and their respective shareholders and creditors under section 230-232 of the Companies Act, 2013, the Company completed the demerger of its Commodity API Business to Solara. Pursuant to the aforesaid Scheme, the Human API business of SeQuent was also demerged to Solara.
Appointed Date and Effective Date for demerger was October 1, 2017 and March 31, 2018, respectively.
The Scheme received nod of the Equity Shareholders of the Company on December 27, 2017 and approval of the National Company Law Tribunal, Mumbai Bench vide its Order dated March 9, 2018.
Consequent to the above, Solara allotted shares to the Equity Shareholders of the Company as at the Record Date, April 9, 2018, as consideration under the Composite Scheme on April 11, 2018. As provided in the Composite Scheme, Solara was listed on the Stock Exchanges (NSE and BSE) on June 27, 2018.
Events Post Balance Sheet Date
6) Strides API Research Centre
On April 20, 2018, the Company entered into Business Purchase Agreement with Solara Active Pharma Sciences Limited, India (Solara) to sell the assets (consisting of Plant & machinery, equipment, computer software and other related capital work in progress) and business conducted by the Company at Strides API Research Centre (SRC) along with the employees for a consideration of Rs.357.28 Million and working capital subject to adjustment and finalisation for Rs.8.26 Million.
The Company has classified the assets of the SRC unit as Assets Held for Sale as on March 31, 2018.
7) Proposed merger of Australian business of Strides and Apotex
The Company and Apotex have agreed in-principle to merge their respective Australian business operations. Currently, Strides is one of the leading generic players in the Australian pharmaceutical market and runs its business under the Arrow brand. Apotex is the leading generic player in the Australian pharmaceutical market and runs its business under the Apotex brand.
The Combination shall enable Strides, through the merged business, to become the leading player in the Australian generic pharmaceutical market by both volume and revenue. The proposed transaction will be EPS accretive from Year 1 through merger synergies. The merged business will have the largest portfolio of owned product IP for the Australian market. Potential synergies will accrue through higher volumes and improved COGS.
Strides and Apotexs business will be run independently under the brands Arrow and Apotex respectively and will continue to enjoy preferred partner relationship with their respective wholesalers. The merged business will continue to be supported by Strides and Apotexs manufacturing facilities and will have approx. 3200 first line pharmacy accounts.
The proposed structure will be arrived through a share swap. The existing hospital business of Apotex will not form part of the merged entity and will be retained by Apotex.
The transaction is subject to entering into definitive agreements between the parties, satisfactory due diligence, customary closing conditions and statutory approvals, including approval of Australian Competition and Consumer Commission.
8) Proposed merger of Arrow Remedies and Fagris Medica into the Company
The Board of Directors of the Company at its meeting held on May 18, 2018 have approved the Scheme of Amalgamation for merger of Arrow Remedies Private Limited and Fagris Medica Private Limited (collectively known as Transferor Companies, which are wholly owned subsidiaries of the Company) into the Company (Transferee Company) in terms of Section 230 to 232 of the Companies Act, 2013.
The Scheme is subject to necessary statutory and regulatory approvals including the approvals of National Company Law Tribunal, the shareholders and creditors of each of the companies.
The appointed date for the said amalgamation is April 1, 2018 or such other date as may be agreed between the Transferor Companies and the Transfree Company and approved by the National Company Law Tribunal.
The Scheme of Amalgamation will enable the Company to consolidate and effectively manage the Transferor Companies and the Company in a single entity, eliminate duplication of operating and administrative expenses and simplify the group structure.
There will not be any change in the shareholding pattern of the Transferee Company pursuant to the Scheme of Amalgamation as both the Transferor Companies are wholly-owned subsidiaries of the Transferee Company.
9) Divestment of Strides Chemicals Private Limited
Pursuant to the approval of the Shareholders of the Company obtained by means of Postal Ballot, the Company proposes to divest its 100% stake in Strides Chemicals to Solara Active Pharma Sciences. The divestment is pursuant to evaluation conducted by the Management and as part of measure to improve and sharpen the focus on the formulations business and profitability of the Company.
As part of the arrangement, Solara has offered the Company long-term development and manufacturing arrangement and a Most Favoured Customer status for all the DMFs required for the integrated formulations portfolio of the Company. The divestment will help Strides become leaner, while retaining supply chain security for the formulations portfolio.
The divestment process is expected to completed post receipt of shareholders approval for the same by Solara.
4. Board of Directors and Key Managerial Personnel as at the date of this Report
Board of Directors of the Company
Mr. Deepak Vaidya, Non-Executive Director, Chairperson of the Board.
Mr. S Sridhar, Mr. Bharat Shah, Ms. Sangita Reddy and Mr. Homi Khusrokhan -Independent Directors of the Company.
Mr. Arun Kumar, Group CEO and Managing Director
Mr. Badree Komandur, Executive Director Finance.
Key Managerial Personnel
Mr. Arun Kumar, Group CEO and Managing Director Mr. Badree Komandur, Executive Director Finance Ms. Manjula Ramamurthy, Company Secretary
Appointment, Re-designation of Director and Retirement by Rotation
1. Mr. Badree Komandur, Executive Director Finance retires by rotation at the ensuing Annual General Meeting and being eligible, offers himself for reappointment.
2. Appointment of Mr. Arun Kumar as Executive Director of the Company for a period of 3 years.
3. Continuation of Mr. Homi Rustam Khusrokhan as Independent Director of the Company till the completion of his current term i.e upto May 17, 2022.
Number of meetings of the Board
During the year under review, the Board met 6 times. Details of the same are provided in the Corporate Governance Report, which is part of this report.
5. Share Capital
The Authorised Share Capital of the Company as at the date of this report is Rs.1,767,500,000/- divided into 176,750,000 equity shares of Rs.10/- each.
The Issued, Subscribed and Paid-up Share Capital of the Company as at the date of this report is Rs.895,489,130/- divided into 89,548,913 equity shares of Rs.10/- each.
There has been an increase in the Paid-up Equity Share Capital of the Company on account of allotment of 125,907 equity shares consequent to exercise of stock options by employees.
Your Directors are pleased to recommend a Dividend of Rs.2/- (Rupees Two Only) per equity share of face value of Rs.10/- each for the financial year ended March 31, 2018, subject to the approval of the shareholders at the ensuing Annual General Meeting, which is scheduled on September 24, 2018.
The Register of Members and Share Transfer Books will remain closed from September 15, 2018 to September 24, 2018 (both days inclusive) for the purpose of payment of final dividend for the financial year ended March 31, 2018 and the AGM.
Dividend, if approved by shareholders, will be paid within 30 days from the date of declaration of dividend.
In terms of Regulation 43(A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Company has adopted a Dividend Distribution Policy. The said Policy is available on the Companys website and can be accessed at http://www.strides.com/investor-committeboard. html
7. Subsidiary, JVs and Associate Companies
As at March 31, 2018, the Company had 51 subsidiaries (46 overseas and 5 India), 3 Joint Ventures (2 overseas and 1 India), 4 Associate Companies (3 overseas and 1 India).
List of subsidiaries/ JVs/ Associates which have become or ceased to be part of the Company is enclosed as Annexure 1
Accounts of Subsidiaries
In accordance with Section 129 (3) of the Companies Act, 2013, the Company has prepared a consolidated financial statement of the Company and all its subsidiary companies, which is forming part of the Annual Report. Statement containing salient features of the financial statements of the subsidiary companies/ joint ventures as required in Form AOC 1 is enclosed as Annexure 2 to this Report.
8. Corporate Governance and Management Discussion and Analysis
As per SEBI Listing Regulations, the Corporate Governance Report with the Auditors Certificate thereon, and the Management Discussion and Analysis forms part of this report.
9. Employee Stock Option Scheme
The Company has 3 ESOP Schemes viz., Strides Arcolab ESOP 2011, Strides Arcolab ESOP 2015 and Strides Shasun ESOP 2016 Schemes.
Statement giving detailed information on stock options granted to Employees under the Companys Employee Stock Option Schemes as required under the SEBI Regulation is enclosed as Annexure 3 to this Report.
10. Particulars of Employees
The statement containing particulars in terms of Section 197 (12) of the Companies Act, 2013 read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of this report and is appended herewith as Annexure 4 to the Boards report.
The statement containing particulars in terms of Section 197(12) of the Companies Act, 2013 read with rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of this report.
Considering the first proviso to Section 136(1) of the Companies Act, 2013, the Annual Report, excluding the aforesaid information, is being sent to the members of the Company and others entitled thereto. The said information is available for inspection at the registered office of the Company during business hours on working days of the Company up to the date of the ensuing Annual General Meeting. Any shareholder interested in obtaining a copy thereof, may write to the Company Secretary in this regard.
11. Corporate Social Responsibility (CSR)
The Company has undertaken "Corporate Social Responsibility (CSR)", initiatives in areas of Health, Education and Employability which are projects in accordance with Schedule VII of the Companies Act, 2013.
A detailed report on CSR activities undertaken during the financial year 2017-18 is enclosed as Annexure 5 to this Report.
12. Loans, Guarantees or Investments
Details of Loans granted, Guarantees given and Investments made during the year under review, covered under the provisions of Section 186 of the Companies Act, 2013 are given in the Note no. 40 to the standalone financial statements in the Annual Report.
13. Contracts or Arrangements with Related Parties
All the transactions with related parties are in the ordinary course of business and at arms length basis. Hence disclosure under Form AOC - 2 is not part of this report. Transactions with related parties are disclosed in Note no. 45 to the standalone financial statements in the Annual Report.
The Company has formulated a policy for transacting with Related Parties, which is uploaded on the Companys website at http://www.strides.com/ investor-committeboard.html
Further, there are no materially significant related party transactions made by the Company which may have potential conflict with the interests of the Company.
14. Auditors and Audit Reports
Secretarial Audit Report
M/s. Gopalkrishnaraj HH & Associates, a firm of Company Secretaries in Practice (Certificate of Practice No: 4152) is the Secretarial Auditor for the Company.
The Secretarial Audit for the financial year 2017-18, inter-alia, included audit of compliance with the Companies Act, 2013, and the Rules made under the Act, SEBI Listing Regulations and applicable Regulations prescribed by SEBI amongst others.
The Secretarial Audit Report is enclosed as Annexure 6 to the Boards Report. The Secretarial Audit Report does not contain any qualifications, reservations or adverse remarks.
During the period under review, M/s Deloitte Haskins & Sells completed their term of appointment and were replaced by M/s B S R & Co. LLP, Chartered Accountants (Firm Registration no. 101248W/ W-100022) as Statutory Auditors of the Company at the 26th AGM held on September 15, 2017.
BSR & Co. LLP, Chartered Accountants holds office for a period of 5 years i.e., till the conclusion of the 31st AGM of the Company to be held in FY 2021-22.
In accordance with Companies (Amendment) Act, 2017 appointment of Statutory Auditors is not required to be ratified at every AGM.
There are no qualifications, observations or adverse remarks in the Audit Report issued by the Statutory Auditors of the Company for financial year ended March 31, 2018.
M/s. Grant Thornton India LLP, Chartered Accountants are the Internal Auditors of the Company. The Internal Auditors carry out audit as per the audit plan defined by the Audit Committee and regularly updates the committee on their internal audit findings at the Committees meeting.
The Internal Auditors were satisfied with the management response on the observation and recommendations made by them during the course of their audit and have expressed satisfaction with the internal systems, controls and process followed by the Company.
M/s. Rao, Murthy & Associates, Cost Accountants has carried out the Cost Audit for the applicable business for the year under review.
The Board of Directors of the Company have appointed M/s. Rao, Murthy & Associates, Cost Accountants, (Firm Registration No.: 000065) as Cost Auditors to audit the cost accounts of the Company for the Financial Year 2018-19.
15. Internal Financial Controls
The Company has in place well defined and adequate framework for Internal Financial Controls ("IFC") as required under Section 134 (5) (e) of the Companies Act, 2013.
During the year under review, such controls were tested and no material weaknesses in their design or operations were observed.
16. Risk Management
The Company has a risk management framework for identification and managing risks. Please refer the "Management Discussion and Analysis" report forming part of the Annual Report for additional details.
17. Other Disclosures
Nature of Business of the Company
There has been no change in the nature of business of the Company during the year under review.
The Company has not accepted any deposits covered under chapter V of the Companies Act, 2013. Accordingly, no disclosure or reporting is required in respect of details relating to deposits.
Whistle Blower Policy
The Company has a Whistle Blower Policy. The Policy provides appropriate avenues to the directors, employees and stakeholders of the Company to make protected disclosures in relation to the matters concerning the Company. Protected Disclosures are appropriately dealt with by the Whistle Officer or the Chairperson of the Audit Committee.
The Policy is also available on the Companys website and can be accessed at http://www.strides.com/ investor-committeboard.html
Policy on Directors Appointment and Remuneration
The policy of the Company on Directors appointment and remuneration, including the criteria for determining qualifications, positive attributes, independence of a director and other matters, as required under Section 178 of the Companies Act, 2013 is available on the
Companys website and can be accessed at http:// www.strides.com/investor-committeboard.html
The assets/ properties of the Company are adequately insured against loss due to fire, riots, earthquake, terrorism, etc., and against other perils that are considered necessary by the management.
Significant and material orders passed by the Regulators or Courts
There are no significant and material orders passed by the Regulators/ Courts that would impact the going concern status of the Company and its future operations.
Extract of Annual Return
Extract of Annual Return in Form MGT 9 is enclosed as Annexure 7 to the Boards Report.
Conservation of Energy, R&D, Technology
Absorption and Foreign Exchange Earnings/ Outgo
Details of Energy Conversation, R&D, Technology Absorption and Foreign Exchange Earnings/ Outgo are enclosed as Annexure 8 to this Report.
18. Declaration by Independent Directors
In accordance with Section 149(7) of the Companies Act, 2013, each independent director has confirmed to the Company that he or she meets the criteria of independence as laid down in Section 149 (6) of the Companies Act, 2013 and Regulation 25 of the SEBI Listing Regulations.
19. Board Evaluation
The evaluation of all the directors, committees, Chairperson of the Board, and the Board as a whole was conducted. The evaluation parameters and the process have been explained in the Corporate Governance Report, which is part of this report.
20. Directors Responsibility Statement
Pursuant to the requirement under clause (c) of subsection (3) of Section 134 of the Companies Act, 2013 with respect to the Directors Responsibility Statement, the Board of Directors of your company state that:
(a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
(b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;
(c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
(d) the directors have prepared the annual accounts of the Company on a going concern basis;
(e) the directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively.
(f) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
Your Directors place on record their sincere appreciation for the significant contribution made by the employees through their dedication, hard work and commitment and the trust and confidence reposed on us by the medical profession and trade.
We also acknowledge the support extended to us by the bankers, financial institutions, Government agencies, analysts, shareholders and investors at large.
|For and on behalf of the Board of Directors|
|Date: August 8, 2018||Deepak Vaidya|
|Place: Bengaluru||Chairperson of the Board|
Details of Subsidiaries
Part A - Entities incorporated in FY 2018
|Sl. No.||Name of the Entity|
|1||Strides Lifesciences Limited, Nigeria||April 10, 2017|
|2||Arrow Life Sciences (Malaysia) Sdn. Bhd, Malaysia||May 11, 2017|
|3||Strides Pharma Canada Inc, Canada||May 11, 2017|
Part B - Entities that became part of Strides Group in FY 2018
|Sl. No.||Name of the Entity|
|1||Vivimed Life Sciences Private Limited, India||May 18, 2017|
|2||Strides Vivimed Pte Ltd, Singapore (formerly, Vivimed Global Generics Pte Ltd)||May 18, 2017|
|3||Amneal Pharma Australia Pty Ltd, Australia||August 31, 2017|
|4||Amneal Pharmaceuticals Pty Ltd, Australia||August 31, 2017|
|5||Trinity Pharma Proprietary Limited, South Africa||January 1, 2018|
|6||Apollo Life Sciences Holdings Proprietary Limited, South Africa||January 1, 2018|
|7||MyPak Solutions Australia Pty Ltd, Australia (formerly, MyPak Solutions Pty Ltd, Australia)||March 29, 2018|
Part C - Entities divested during the FY 2018
|Sl. No.||Name of the Entity|
|1||Strides Healthcare Private Limited, India||December 1, 2017|
|2||Divestment pursuant to Scheme of Demerger||Appointed Date:|
|October 1, 2017|
|a. Solara Active Pharma Sciences Limited, India||Effective Date:|
|b. Chemsynth Laboratories Private Limited, India||March 31, 2018|
|c. Shasun USA Inc, USA|
Part D Entities wound up/ merged during FY 2018
|Sl. No.||Name of the Entity|
|1||Akorn Strides LLC, USA||Wound up||August 4, 2017|
|2||Shasun NBI LLC, USA||Wound up||October 25, 2017|
|3||Strides Africa Limited, BVI||Wound up||March 7, 2018|
|4||Strides Pharma Limited, Cyprus||Merged with Strides Pharma||December 12, 2017|
|International Limited, Cyprus|
FORM AOC 1
(Pursuant to first proviso to sub section (3) of Section 129 read with Rule 5 of Companies (Accounts) Rules, 2014) (Statement containing salient features of the financial statement of subsidiaries/associate companies/ joint ventures)
Part A - Subsidiaries
|SI. No.||Name of the Subsidiary||Country of incorporation||Reporting Currency||Exchange Rate||Capital (Includes Monies pending allotment)||Reserves||Total Assets||Total liabilities (other than Capital & reserves)||Investments other than in subsidiaries||Turnover||Profit before taxation||Provision for taxation||Profit after taxation||Proposed dividend||Share- holding (%)|
|1||Alliance Pharmacy Pty Limited||Australia||AUD||49.92||-||-||-||-||-||-||-||-||-||-||100%|
|2||Altima Innvovations Inc.||USA||USD||65.16||-||(172.58)||11.82||184.40||-||5.24||(16.62)||-||(16.62)||-||100%|
|3||Amneal Pharma Australia Pty Ltd||Australia||AUD||49.92||-||-||-||-||-||-||-||-||-||-||100%|
|4||Amneal Pharmaceuticals Pty Ltd||Australia||AUD||49.92||3,982.81||(3,160.05)||1,005.78||183.02||36.17||1,184.08||344.86||36.62||308.24||-||100%|
|5||Apollo Life sciences Holding Proprietary Limited||South Africa||ZAR||5.54||-||(0.91)||25.16||26.07||-||46.19||(0.09)||-||(0.09)||-||100%|
|6||Arrow Life Sciences (Malaysia) Sdn. BHD||Malaysia||MYR||16.83||0.93||(0.23)||0.72||0.02||-||-||(0.22)||-||(0.22)||-||100%|
|7||Arrow Pharma (Private) Limited||Sri Lanka||LKR||0.42||21.04||(17.85)||3.30||0.11||-||2.04||8.89||-||8.89||-||100%|
|8||Arrow Pharma Life Inc.||Philippines||PHP||1.24||11.94||(8.04)||4.06||0.16||-||0.59||(1.07)||-||(1.07)||-||100%|
|9||Arrow Pharma Pte Limited||Singapore||USD||65.16||55.03||(122.62)||(63.07)||4.52||-||9.11||(61.47)||-||(61.47)||-||100%|
|10||Arrow Pharma Pty Limited||Australia||AUD||49.92||-||-||-||-||-||-||-||-||-||-||100%|
|11||Arrow Pharmaceuticals Pty Limited||Australia||AUD||49.92||5,881.77||80.03||8,495.74||2,533.94||0.54||6,009.09||333.65||81.53||252.12||-||100%|
|12||Arrow Remedies Private Limited||India||INR||1.00||0.10||(0.44)||(0.10)||0.24||-||1.15||0.55||0.17||0.38||-||100%|
|14||Chemsynth Laboratories Private Limited*||India||INR||1.00||-||-||-||-||-||-||(0.04)||-||(0.04)||-||0.00%|
|15||Fagris Medica Private Limited||India||INR||1.00||10.40||(9.39)||8.99||7.98||-||12.82||0.06||-||0.06||-||100%|
|16||Generic Partners Holding Co. Pty Limited||Australia||AUD||49.92||741.14||7.72||753.85||4.99||-||-||(1.81)||-||(1.81)||-||51%|
|17||Generic Partners Pty Limited||Australia||AUD||49.92||741.22||(362.04)||1,060.06||680.88||-||1,453.31||(83.75)||(78.24)||(5.51)||-||100%|
|18||Generic Partners (Canada) Inc||Canada||CAD||50.42||0.01||31.30||134.10||102.79||-||85.98||82.55||6.30||76.25||-||100%|
|19||Generic Partners (International) Pte Limited||Singapore||SGD||49.67||7.27||(0.01)||15.42||8.16||-||-||(0.57)||-||(0.57)||-||51%|
|20||Generic Partners (M) SDN BHD||Malaysia||MYR||16.83||-||(0.02)||0.46||0.48||-||-||(0.38)||-||(0.38)||-||100%|
|21||Generic Partners (NZ) Limited||New Zealand||NZD||47.05||-||(2.32)||-||2.32||-||-||(0.36)||-||(0.36)||-||100%|
|22||Generic Partners (SA) Pty Limited||South Africa||ZAR||5.54||-||(0.02)||-||0.02||-||-||-||-||-||-||100%|
|23||Generic Partners UK Limited||UK||GBP||91.73||0.01||57.13||79.11||21.97||-||354.05||36.12||5.29||30.83||-||100%|
|24||Pharmacy Alliance Group Holdings Pty Limited||Australia||AUD||49.92||1,358.21||(1,358.22)||29.27||29.28||-||19.97||19.96||-||19.96||19.97||51%|
|25||Pharmacy Alliance Investments Pty Limited||Australia||AUD||49.92||704.77||29.28||734.05||-||-||10.18||10.18||-||10.18||-||100%|
|26||Pharmacy Alliance Pty Limited||Australia||AUD||49.92||74.18||171.48||572.17||326.51||-||817.79||140.51||45.04||95.47||19.97||100%|
|27||Shasun Foundation Trust||India||INR||1.00||-||-||-||-||-||-||(0.03)||-||(0.03)||-||0.00%|
|28||Shasun Pharma Solutions Inc.||USA||USD||65.16||35.67||(36.06)||-||0.39||-||-||(0.13)||0.07||(0.20)||-||100%|
|29||Shasun USA Inc.*||USA||USD||65.16||-||-||-||-||-||(1.44)||201.75||-||201.75||-||0.00%|
|30||Smarterpharm Pty Limited||Australia||AUD||49.92||0.07||29.51||42.12||12.54||-||36.73||28.81||7.32||21.49||-||100%|
|31||Solara Active Pharma Sciences Limited*||India||INR||1.00||-||-||-||-||-||-||(3.80)||-||(3.80)||-||0.00%|
|32||Stabilis Pharma Inc.||USA||USD||65.16||0.06||0.04||0.33||0.23||-||-||(0.14)||0.08||(0.22)||-||100%|
|33||Stelis Biopharma (Malaysia) SDN. BHD.||Malaysia||MYR||16.83||140.03||(58.61)||81.63||0.21||-||-||(13.95)||-||(13.95)||-||100%|
|34||Strides Africa Limited**||British Virgin Islands||USD||65.16||-||-||-||-||-||-||(0.13)||-||(0.13)||-||0.00%|
|35||Strides Arcolab (Australia) Pty Limited||Australia||AUD||49.92||5,973.88||(111.68)||9,130.19||3,267.99||-||(3.02)||(127.33)||-||(127.33)||-||99.99%|
|36||Strides Arcolab International Limited||UK||USD||65.16||4,004.50||355.37||4,369.33||9.46||92.15||0.22||(148.21)||-||(148.21)||-||100%|
|37||Strides Chemicals Private Limited||India||INR||1.00||797.00||498.01||1,495.23||200.22||-||353.11||(165.87)||-||(165.87)||-||100%|
|38||Strides CIS Limited||Cyprus||USD||65.16||0.20||12.72||72.81||59.89||-||114.36||4.97||-||4.97||-||100%|
|39||Strides Consumer Private Limited||India||INR||1.00||0.10||(168.60)||(11.38)||157.12||-||11.89||(168.60)||-||(168.60)||-||100%|
|40||Strides Emerging Markets Limited (formerly, Strides Emerging Markets Private Limited)||India||INR||1.00||56.27||(143.41)||175.86||263.00||-||72.19||(124.17)||-||(124.17)||-||100%|
|41||Strides Foundation Trust||India||INR||1.00||-||32.50||35.96||3.46||-||0.78||9.20||-||9.20||-||100%|
|42||Strides Healthcare Private Limited||India||INR||1.00||-||-||-||-||-||6.20||(26.02)||(7.96)||(18.06)||-||0.00%|
|43||Strides Life Sciences Limited||Nigeria||NGN||0.18||0.53||(37.70)||211.95||249.12||-||70.86||(39.76)||-||(39.76)||-||100%|
|44||Strides Pharma (Cyprus) Limited||Cyprus||USD||65.16||912.43||1,029.27||2,586.63||644.93||-||1,278.70||(1,211.31)||4.97||(1,216.28)||-||100%|
|45||Strides Pharma (SA) Pty Limited||South Africa||ZAR||5.54||-||(9.55)||37.29||46.84||-||-||(5.14)||-||(5.14)||-||100%|
|46||Strides Pharma Global (UK) Limited (formerly Strides Pharma (UK) Limited)||UK||GBP||91.73||3,977.13||(2,062.26)||2,273.95||359.08||101.41||(0.11)||0.73||-||0.73||-||100%|
|47||Strides Pharma Asia Pte Limited||Singapore||USD||65.16||10,447.08||(37.60)||10,496.46||86.98||-||185.37||(635.28)||1.62||(636.90)||-||100%|
|48||Strides Pharma Canada Inc||Canada||CAD||50.42||0.05||(1.11)||0.05||1.11||-||-||(1.11)||-||(1.11)||-||70%|
|49||Strides Pharma Global Pte Limited||Singapore||USD||65.16||11,013.17||2,631.76||31,307.60||17,662.67||-||6,187.72||1,020.32||86.52||933.80||-||100%|
|50||Strides Pharma Inc.||USA||USD||65.16||8.45||1,433.66||4,949.38||3,507.27||-||2,675.48||(758.63)||0.12||(758.75)||-||100%|
|51||Strides Pharma International Limited||Cyprus||USD||65.16||28.54||1,218.62||1,553.64||306.48||-||204.37||146.00||3.25||142.75||493.74||100%|
|52||Strides Pharma Limited***||Cyprus||USD||65.16||-||-||-||-||-||49.49||3.61||13.04||(9.43)||202.00||-|
|53||Strides Pharma UK Limited (formerly Strides Shasun (UK) Limited)||UK||GBP||91.73||-||-||390.83||79.30||-||-||-||-||-||-||100%|
|54||Strides Shasun Latina, SA de CV||Mexico||MXN||3.54||13.00||(4.42)||18.39||9.81||-||(0.26)||(4.35)||-||(4.35)||-||80%|
|55||Strides Specialties (Holdings) Limited||Mauritius||USD||65.16||-||-||-||-||-||1.63||1.51||-||1.51||-||100%|
|56||Strides Vivimed Pte Ltd (formerly Vivimed Global Generics Pte Limited)||Singapore||USD||65.16||185.54||(15.16)||170.22||(0.16)||-||0.01||(15.00)||-||(15.00)||-||50%|
|57||SVADS Holdings SA||Switzerland||CHF||68.11||466.59||232.79||788.51||89.13||-||32.57||(245.37)||-||(245.37)||-||100%|
|58||Trinity Pharma Proprietary Limited||South Africa||ZAR||5.54||0.01||32.65||546.31||513.65||-||198.69||7.91||2.84||5.07||-||51.76%|
|59||Universal Corporation Limited||Kenya||KES||0.64||117.47||883.59||2,281.02||1,279.96||-||1,382.56||64.44||67.38||(2.94)||-||51%|
*Ceased to be part of the Group pursuant to Composite Scheme of Demerger, effective date of the demerger being March 31, 2018 **Wound up effective March 7, 2018 ***Strides Pharma Limited, Cyprus merged with Strides Pharma International Limited effective December 12, 2017
Part B - Associates/ Joint Venture
Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures
|SI. No.||Name of Associate / Joint Venture||Stelis Biopharma Private Limited, India||Regional Bio Equivalence Centre S.C., Ethiopia||Aponia Laboratories Inc, USA||Akorn Strides LLC, USA||Shasun NBI LLC, USA||Oraderm Pharmaceuticals Pty Limited, Australia||Vivimed life Sciences Private Limited, India||Mypak Solutions Australia Pty Limited, Australia||Generic Partners ( R&D) Pte. Ltd, Singapore|
|1||Latest audited Balance Sheet Date||
March 31, 2018
December 31, 2017
March 31, 2018
Akorn Strides LLC does not have an independent audit performed in its financials, they are incorporated in the audit conducted on Akorn Inc., USA
March 31, 2017
March 31, 2018
Newly incorporated entity
|2||Shares of Associate/ Joint Venture held by the Company on the year end No.||251,527 shares||342 shares||3,734,074 shares||-||-||50 shares||14,133,440 shares||51 shares||19 shares|
|Amount of Investment in Associate/ Joint Venture Extent of Holding %||Rs.1905.36 Million||Nil||Rs.92.15 Million||Nil||Nil||Rs.0.54 Million||Rs.629.38 Million||Rs.36.17 Million||Nil|
|3||Description of how there is significant influence||53.47% and board representation||24.98%||24% and board representation||50%||50%||50% and board representation||50% and board representation||50.495% and board representation||19% and board representation|
|4||Reason why the Associate/ Joint Venture is not consolidated||Not Applicable||Not Applicable||Not Applicable||The JV has been wound up during the year.||The JV has been wound up during the year.||Not Applicable||Not Applicable||Not Applicable||Not Applicable|
|5||Networth attributable to Shareholding as per latest auditied Balance Sheet||Rs.1120.19 Million||Rs.28.31 Million||Nil||Nil||Rs..50 Million||Rs.635.91 Million|
|6||Profit/ (Loss) for the year Considered in Consolidation Not considered in Consolidation||(Rs.144.06) Million||(Rs.3.14) Million||Rs.8.59 Million||Nil||Nil||Nil||(Rs.29.38) Million||Nil||Nil|
Details of Strides Employee Stock Options pursuant to SEBI Regulation and Companies Act, 2013
As at March 31, 2018, the Company had three ESOP schemes viz., Strides Arcolab ESOP 2011, Strides Arcolab ESOP 2015 and Strides Shasun ESOP 2016 Scheme.
With respect to the above, please find below the details of Employee Stock Options pursuant to SEBI Regulation and Companies Act, 2013 as at March 31, 2018.
|Sl. No.||Description||Strides Arcolab||Strides Arcolab||Strides Shasun ESOP 2016|
|ESOP 2011||ESOP 2015|
|A||Options available under the Scheme||15,00,000||70,000||30,00,000|
Decided by the Compensation Committee from time to time, which shall be, not less than 85% of the market price of the shares on the date of grant of option.
This ESOP Scheme is exclusively for erstwhile Shasun employees who were holding stock options under the Shasun ESOP Plan and became part of the Strides Group pursuant to merger of Shasun Pharmaceuticals with Strides in FY 2015-16. In terms of the Scheme of Amalgamation between the two companies, Exercise Price per equity share of the Company shall be equal to the quotient of the option of the Shasun Exercise Price per equity share divided by the Share Exchange Ratio (rounded up to the nearest higher whole cent). This would translate to 0.3125 (5/16) New Stock Options in the Company, in relation to each option granted under the Shasun - ESOP Plan 2012. Accordingly, the Exercise price per New Stock Option is Rs.273.92 per Share of the Company
Decided by the Compensation Committee from time to time, which shall be, not less than 75% of the market price of the shares on the date of grant of option.
|C||Outstanding options as at April 1, 2017||1,70,000||23,097||1,00,000|
|D||Options granted during the year under review||NIL||NIL||2,00,000|
|E||Options vested during the year under review||170,000||16,157||20,000|
|F||Options exercised during the year under review||50,000||7,029||20,000|
|G||Total number of shares arising as a result of exercise of options||50,000||7,029||20,000|
|H||Options lapsed / surrendered during the year under review||80,000||5,376||-|
|I||Variation of terms of options||-||-||-|
|J||Money realised by exercise of options||1,61,15,000||19,25,384||1,68,25,000|
|K||Total number of options in force at the end of the period ending March 31, 2018||40,000||10,692||2,80,000|
|L||Available for further grant||NIL Refer Note 1||NIL Refer Note 2 & 3||27,00,000|
|M||Employee-wise details of options granted during the year under review|
|(i) Key Management Personnel||NONE||NONE||1,00,000 options|
|(i) Any other employee who received grant in any one year of option amounts to 5% or more of options during the year||NONE||NONE||1,00,000 options|
|(i) Identified employees who were granted options, during any one year, equal or exceeding 1% of the issued capital (excluding outstanding warrants and conversion) of the Company at the time of grant||NONE||NONE||NONE|
|N||Diluted Earnings Per Share (DEPS) pursuant to issue of shares on exercise of option calculated in accordance with Indian Accounting Standard (IND AS) - 33 Earnings Per Share||Continuing Operations||17.48|
|O||Where the Company has calculated the employee compensation cost using the intrinsic value of the stock options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the option, shall be disclosed. The impact of the difference on profits and EPS of the Company shall be disclosed.||The Compensation cost has been accounted under fair value.|
|P||Weighted Average exercise price of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock||Rs. 322.30||Rs.273.92||Rs.841.25|
SEBI had notified the Share Based Employee Benefits Regulations 2014 which replaced the erstwhile ESOP guidelines. It mandates that all listed companies having existing stock option schemes comply with the revised regulation in their entirety.
Considering the above, the Nomination and Remuneration Committee resolved that it shall not grant further stock options under the ESOP 2011 Scheme. However, the outstanding options under the ESOP 2011 shall continue to vest as per the offer letter granted to employees of the Company.
ESOP 2015 was an exclusive Scheme for the employees of erstwhile Shasun Pharmaceuticals and its subsidiaries which merged into Strides. Under the Scheme, 30,625 options were granted to employees of erstwhile Shasun and 6,813 options were granted to employees of its subsidiary.
Stock Options as per the Scheme of Arrangement to all Eligible Employees of erstwhile Shasun have already been granted and no further grant is pending under the Scheme.
Pursuant to Demerger of Commodity API business of the Company to Solara Active Pharma Sciences Limited, the Company accelerated vesting of 9,128 stock options under the Strides Arcolab ESOP 2015 Scheme held by identified employees who were transferred to Solara. Out of the accelerated options, 8,878 options were exercised by the employees.
Details pursuant to Section 197 of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014
|a The ratio of the remuneration of each director to the median remuneration of the employees of the Company for the financial year ending March 31, 2018||As at March 31, 2018, the Board comprised of 8 Directors - comprising of 2 Executive Directors, 4 Independent Directors and|
|2 Non-Executive Directors.|
|The Non-Executive & Independent Directors receive sitting fees of Rs.100,000/- for attending each meeting of the Board and Audit Committee (effective August 11, 2017. Prior to August 11, 2017, the siting fees paid was Rs.50,000/-). They do not receive any other form of remuneration. The ratio of remuneration of the Executive Directors of the Company to the median remuneration of the employees of the Company for the financial year ended March 31, 2018 are as below:|
|1) Mr. Arun Kumar, Non-Executive Director1 - 28|
|2) Mr. Abhaya Kumar Shankarlal, Executive Director2 - 24|
|3) Mr. Shashank Sinha, Managing Director3 - 131|
|4) Mr. Badree Komandur, Executive Director - Finance4 - 56|
|The median remuneration for the period under review is Rs. 496,500/- per annum (without considering the Sitting Fees paid to Non-Executive & Independent Directors of the Company).|
|b. The percentage increase in remuneration of each Director, Chief Executive Officer, Chief Financial Officer, Company Secretary in the financial year ending March 31, 2018:|
|# Particulars||% Increase|
|1) Mr. Arun Kumar||0%|
|2) Mr. Abhaya Kumar Shankarlal||0%|
|3) Mr. Shashank Sinha||10%|
|4) Mr. Badree Komandur4||9%|
|Executive Director - Finance|
|5) Ms. Manjula Ramamurthy||68%|
|c. The percentage increase in the median remuneration of employees in the financial year ending March 31, 2018||13%|
|d. The number of permanent employees on the rolls of Company as at March 31, 2018||2,507 Employees|
|e. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration||The average annual increase across the organisation was around 13%.|
The Company affirms remuneration to the Directors and Key Managerial Personnel is as per the remuneration policy of the Company.
1Re-designated as Non-Executive Director effective May 18, 2017. 2Resigned as Executive Director effective May 18, 2017.
3Appointed as Managing Director effective May 18, 2017
4Appointed as Executive Director - Finance effective May 18, 2017
Particulars on Energy Conservation and Technology Absorption
(A) Conservation of Energy
(i) Steps taken and impact on conservation of energy a) 1,87,300 KL of process water treated by waste water treatment plants and reused for garden/lawn inside the plant premises across all sites in India.
85000 KL process water was treated in ZLD & reused for non process usage in API Puducherry.
30000 KL RO Reject was recycled & reused for non process usage in API Cuddalore.
b) 58,260 KL of water recycled from steam condensate and reused for steam generation across all sites.
c) 8,717 KL rain water collected and recharged to improve the ground water table across all sites.
d) Replacement of TFL/CFL/SVL with energy efficient LED lights resulted in saving of about 4,80,370 kWh across all sites.
(ii) Steps taken by the Company for utilising alternative sources of energy a) Utilisation of 12.82 MU renewable energy resulted in 6,795 MT CO2 emissions reduction across all sites.
b) Utilised Indian Energy Exchange and Power Exchange of India as alternate energy sources and consumed 9.17 MU across all sites in India.
(B) Technology absorption:
(i) E_orts made towards technology absorption are: At Oral Dosage Facility Bengaluru a) Tablet Inspection system in two CVC Bulk filling lines commissioned to detect & reject tablets/Hard gel capsules not meeting acceptance criteria.
b) 200 BPM High speed Bulk filling line commissioned.
At Oral Dosage facility Puducherry a) Tablet Inspection system in three CVC Bulk
filling lines commissioned to detect & reject tablets/Hard gel capsules not meeting acceptance criteria.
b) Installed automatic moving pallet station of 1000 pallet capacity for FG.
c) 5 Fully automated KRAEMER UTS 4.1 Tablet testing machines installed for improved compliance.
At API facility Cuddalore a) High efficiency water chillers with screw compressors and eco friendly R-134a refrigerant installed for process cooling application resulted in power savings of 589750 KWH per year.
At API facility Puducherry a) 6 Ultra high performance liquid chromatography Instruments, 5 Gas chromatography Instruments with Liquid auto samplers, 1 ICP MS, 2 Gas chromatography Instruments are installed in Quality Control Laboratory to improve the lab testing capabilities.
At API facility Ambernath a) Microbiology lab is upgraded from ISO Class - 8 (Grade-D) to ISO Class -7 (Grade-C) without any additional HVAC/Area modifications in the existing facility.
b) -35C customised set up is made with dry ice arrangement for R&D batches (Cinacalcet).
SSRC Chennai a) New Pharma refrigerator installed for storage of organic lab raw materials requiring low temp storage conditions in place of multiple low volume refrigerators.
(ii) Product Improvement & Technology Absorption: At Oral Dosage Facility Bengaluru a) MES (Manufacturing Execution System - eBMR) implemented successfully for tablet manufacturing process. First Product - LNZ Tablets are being manufactured consistently.
b) Cycle time improved by 30 % in LNZ tablets Coating process.
c) Frusemide Tablets 500mg technical issues in manufacturing resolved and commercial volumes are being delivered.
d) The productivity improvement is achieved by carrying out about 8 batch size changes.
e) The products are validated with alternate equipments in 19 products to accommodate the business requirement and there by achieve customer satisfaction.
f) The sustainability of existing products achieved from the challenges of existing sources, regulatory requirements by carrying out source change validations for 6 products.
g) 26 products from the existing lots which were giving less productivity and in turn creating road block for smooth deliveries due to efficiency and quality compliance are now improved and made more robust. This has helped in achieving an improvement of their performance.
h) 13 products from the recent added Arrow basket of products are site transferred to the in-house manufacturing facilities.
i) 3 commercial launches for US market are achieved to have the higher share in regulated market.
j) Product Robustness Drive resulted in Improved quality and productivity in the following products Prochlorperazine Maleate tab 5 mg Methoxsalen Capsules USP 10 mg Vancomycin Caps 125 mg & 250 mg. Prednisone Tabs 1 mg.
Camvit plus capsules.
Frusemide Tablets 20mg, 40 mg & 500mg.
Efavirenz Tabs 200 mg & 600mg. Prednisone Tabs 25 mg.
At Oral Dosage facility Puducherry a) Improved the productivity of 4 products by increasing the compression machine speed and reduced the sticking frequency of products for overall efficiency.
b) 6 products were launched in Arrow basket of products & are site transferred to the in-house manufacturing facilities.
c) 4 commercial launches for US market are achieved to have the higher share in regulated market.
d) Mesalamine capsules 250 mg & 500 mg Scale up batch successfully completed in higher capacity wurster coater (FBE 500 C).
(iii) In case of import technology (imported during the last three years), the year of Import whether the technology has been fully absorbed:
Integrated High speed counting line from CVC From Taiwan commissioned in Bengaluru site to deliver 200 BPM with improved controls and compliance
Dedicated Fully automated KRAEMER UTS 4.1 Tablet testing machines from Switzerland installed in 5 compression machine cubicles in Puducherry site to check compressed tablet parameters for improved compliance and efficiency.
Expenditure on R&D:
|Rs. in Million|
|Particulars||March 31, 2018||March 31, 2017|
Total Foreign Exchange Earned and Used
|Rs. in Million|
|Particulars||Year ended March 31, 2018|
|Foreign exchange earned in terms of actual inflows||15,697.12|
|Foreign exchange outgo in terms of actual outflows||735.42|
|For and on behalf of the Board of Directors|
|Date: August 8, 2018||Deepak Vaidya|
|Place: Bengaluru||Chairperson of the Board|